4Xu, Y.and M,A. Villalona-Calero, lrinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity [J]. Ann Oncol, 2002, 13(12) : 1841-51.
5Birnbaum, A. and N. Ready, Gefitinib therapy for non-small cell lung cancer [J]. Curr Treat Options Oncol, 2005, 6(1) : 75-81.
6Kuroda, H, et al, Antitumor effect of bisbenzylisoquinoline alkaloids [J]. Chem Pharm Bull (Tokyo), 1976, 24(10) : 2413-20.
7Gardner, C. R, Anticancer drug development based on modulation of the Bcl-2 family core apoptosis mechanism[J].Expert Rev Anticancer Ther, 2004, 4(6) : 115-77.
8Sun, A. X, et al. Synergistic anticancer effects of tetrandrine combined with doxorubicin or vincristine in vitro [J].Zhongguo Yao Li Xue BaD, 1999, 20(1) : 69-73.
10Chen, Y.J, et al. Protective effect of tetrandrine on normal human mononuclear cells asainst ionizing irradiation [J].Biol Pharm Bull, 1997, 20(11) : 1160-4.
3E. Raymond,S. G. Chaney,A. Taamma,E. Cvitkovic>. Oxaliplatin: A review of preclinical and clinical studies[J] 1998,Annals of Oncology(10):1053～1071
4Martin J. Edelman,David R. Gandara,Edith A. Perez,Derrick Lau,Ignacio Lauder,Corrine Turrell,Margaret Uhrich,Frederick Meyers. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy[J] 1998,Investigational New Drugs(1):69～75
3Ravdin D,Erban J,Overmoyer B. Phrase Ⅲ comparison of docetaxel and paclitaxel in patient with meta-static breast cancer (MBC)[J].Eur J Cancer Suppl,2003,(05):S201.
4Walter J,Loos,Felix E,de Jongh,Alex Sparreboom. Evaluation of an Alternate Dosing Strategy for Cisplatin inPatients With Extreme Body Surface Area Values[J].{H}Journal of Clinical Oncology,2006,(10):1499-1505.
